Enovix price target lowered to $15 from $25 at Benchmark

Benchmark lowered the firm’s price target on Enovix (ENVX) to $15 from $25 and keeps a Buy rating on the shares. As the company moves from product sampling in 2025 to product launches in 2026, the speed of the ramp remains subject to customer orders and will likely begin with a relatively modest order before ramping up, says the analyst, who now estimates 2026 revenue of $106.4M, down from a prior estimate of $144.5M.